{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:48:25Z","timestamp":1791902905442,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"DOI":"10.7759\/cureus.117858","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:22:06Z","timestamp":1791901326000},"source":"Crossref","is-referenced-by-count":0,"title":["Artificial Intelligence-Enabled Pharmacovigilance for Neuropsychiatric Therapies: Advancing U.S. Drug Safety Surveillance and Regulatory Decision-Making"],"prefix":"10.7759","author":[{"given":"Rebecca A","family":"Omachonu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A","family":"Uzuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Akinola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Ovabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Odibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Results from the 2021 National Survey on Drug Use and Health (NSDUH). key substance use and mental health indicators in the United States. (2023). Accessed: October 6, 2026: https:\/\/library.samhsa.gov\/product\/results-2021-national-survey-drug-use-and-health-nsduh-key-substance-use-and-menta...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler RC","year":"2012","unstructured":"Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012, 21:169-84. 10.1002\/mpr.1359","journal-title":"Int J Methods Psychiatr Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2015.02.003","article-title":"The prevalence of posttraumatic stress disorder in Operation Enduring Freedom\/Operation Iraqi Freedom (OEF\/OIF) Veterans: a meta-analysis","volume":"31","author":"Fulton JJ","year":"2015","unstructured":"Fulton JJ, Calhoun PS, Wagner HR, et al.. The prevalence of posttraumatic stress disorder in Operation Enduring Freedom\/Operation Iraqi Freedom (OEF\/OIF) Veterans: a meta-analysis. J Anxiety Disord. 2015, 31:98-107. 10.1016\/j.janxdis.2015.02.003","journal-title":"J Anxiety Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg PE","year":"2021","unstructured":"Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021, 39:653-65. 10.1007\/s40273-021-01019-4","journal-title":"Pharmacoeconomics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal JH","year":"2019","unstructured":"Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: a paradigm shift for depression research and treatment. Neuron. 2019, 101:774-8. 10.1016\/j.neuron.2019.02.005","journal-title":"Neuron"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris R","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, et al.. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021, 384:1402-11. 10.1056\/NEJMoa2032994","journal-title":"N Engl J Med"},{"key":"ref7","unstructured":"The importance of pharmacovigilance. safety monitoring of medicinal products. (2002). Accessed: October 6, 2026: https:\/\/apps.who.int\/iris\/handle\/10665\/42493."},{"key":"ref8","unstructured":"Postmarket drug safety information for patients and providers. (2026). Accessed. October 6, 2026: https:\/\/www.fda.gov\/drugs\/surveillance\/postmarket-drug-safety-information-patients-and-providers."},{"key":"ref9","unstructured":"Adverse Event Reporting System (FAERS) quarterly data extract files. (2024). Accessed. October 6, 2026: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1014427","article-title":"Developing the Sentinel system - a national resource for evidence development","volume":"364","author":"Behrman RE","year":"2011","unstructured":"Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel system - a national resource for evidence development. N Engl J Med. 2011, 364:498-9. 10.1056\/NEJMp1014427","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1809643","article-title":"The FDA Sentinel initiative - an evolving national resource","volume":"379","author":"Platt R","year":"2018","unstructured":"Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, Sherman RE. The FDA Sentinel initiative - an evolving national resource. N Engl J Med. 2018, 379:2091-3. 10.1056\/NEJMp1809643","journal-title":"N Engl J Med"},{"key":"ref12","unstructured":"Postmarketing studies and clinical trials - implementation of section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act. (2019). Accessed. October 6, 2026: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/postmarketing-studies-and-clinical-trials-im...."},{"key":"ref13","unstructured":"Risk evaluation and mitigation strategies (REMS). (2024). Accessed. October 6, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System","volume":"90","author":"Gastaldon C","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Psychother Psychosom. 2021, 90:41-8. 10.1159\/000510703","journal-title":"Psychother Psychosom"},{"key":"ref15","unstructured":"Supplement approval letter, NDA 211243\/S-029. SPRAVATO (esketamine) nasal spray, REMS modification. (2026). Accessed: October 6, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2026\/211243Orig1s029ltr.pdf."},{"key":"ref16","unstructured":"FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug clozapine. (2025). Accessed. October 6, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-removes-risk-evaluation-and-mitigation-strategy-rems-progr...."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1229.58825","article-title":"Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications","volume":"8","author":"Andrade C","year":"2010","unstructured":"Andrade C. Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications. Mens Sana Monogr. 2010, 8:146-50. 10.4103\/0973-1229.58825","journal-title":"Mens Sana Monogr"},{"key":"ref18","article-title":"Real-world data on SSRI antidepressant side effects","volume":"6","author":"Cascade E","year":"2009","unstructured":"Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009, 6:16-8.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell L","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006, 29:385-96. 10.2165\/00002018-200629050-00003","journal-title":"Drug Saf"},{"key":"ref20","unstructured":"Suicidality in children and adolescents being treated with antidepressant medications. (2004). Accessed. October 6, 2026: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm161679.htm."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.3.332","article-title":"Suicidality in pediatric patients treated with antidepressant drugs","volume":"63","author":"Hammad TA","year":"2006","unstructured":"Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006, 63:332-9. 10.1001\/archpsyc.63.3.332","journal-title":"Arch Gen Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz R","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012, 91:1010-21. 10.1038\/clpt.2012.50","journal-title":"Clin Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0218-z","article-title":"Text mining for adverse drug events: the promise, challenges, and state of the art","volume":"37","author":"Harpaz R","year":"2014","unstructured":"Harpaz R, Callahan A, Tamang S, et al.. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf. 2014, 37:777-90. 10.1007\/s40264-014-0218-z","journal-title":"Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01505-6","article-title":"Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health\/medical records: a scoping review","volume":"48","author":"Golder S","year":"2025","unstructured":"Golder S, Xu D, O'Connor K, Wang Y, Batra M, Hernandez GG. Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health\/medical records: a scoping review. Drug Saf. 2025, 48:321-37. 10.1007\/s40264-024-01505-6","journal-title":"Drug Saf"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA - a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA - a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-3467(07)60142-6","article-title":"Writing narrative literature reviews for peer-reviewed journals: secrets of the trade","volume":"5","author":"Green BN","year":"2006","unstructured":"Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006, 5:101-17. 10.1016\/S0899-3467(07)60142-6","journal-title":"J Chiropr Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998-2005","volume":"167","author":"Moore TJ","year":"2007","unstructured":"Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007, 167:1752-9. 10.1001\/archinte.167.16.1752","journal-title":"Arch Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez E","year":"2009","unstructured":"Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009, 32:19-31. 10.2165\/00002018-200932010-00002","journal-title":"Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1529100614531398","article-title":"The impact of mental illness stigma on seeking and participating in mental health care","volume":"15","author":"Corrigan PW","year":"2014","unstructured":"Corrigan PW, Druss BG, Perlick DA. The impact of mental illness stigma on seeking and participating in mental health care. Psychol Sci Public Interest. 2014, 15:37-70. 10.1177\/1529100614531398","journal-title":"Psychol Sci Public Interest"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61817-6","article-title":"Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey","volume":"373","author":"Thornicroft G","year":"2009","unstructured":"Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet. 2009, 373:408-15. 10.1016\/S0140-6736(08)61817-6","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20509","article-title":"The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management","volume":"17","author":"Montejo AL","year":"2018","unstructured":"Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. 2018, 17:3-11. 10.1002\/wps.20509","journal-title":"World Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111682","article-title":"Diagnostic overshadowing and other challenges involved in the diagnostic process of patients with mental illness who present in emergency departments with physical symptoms - a qualitative study","volume":"9","author":"Shefer G","year":"2014","unstructured":"Shefer G, Henderson C, Howard LM, Murray J, Thornicroft G. Diagnostic overshadowing and other challenges involved in the diagnostic process of patients with mental illness who present in emergency departments with physical symptoms - a qualitative study. PLoS One. 2014, 9:e111682. 10.1371\/journal.pone.0111682","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda T","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013, 10:796-803. 10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate A","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009, 18:427-36. 10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff JS","year":"2007","unstructured":"Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007, 82:157-66. 10.1038\/sj.clpt.6100258","journal-title":"Clin Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2165\/11534410-000000000-00000","article-title":"Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling","volume":"33","author":"Alvarez Y","year":"2010","unstructured":"Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010, 33:475-87. 10.2165\/11534410-000000000-00000","journal-title":"Drug Saf"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente A","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007, 30:891-8. 10.2165\/00002018-200730100-00007","journal-title":"Drug Saf"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman KB","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014, 37:283-94. 10.1007\/s40264-014-0150-2","journal-title":"Drug Saf"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107087976","article-title":"A new self-rating scale for detecting atypical or second-generation antipsychotic side effects","volume":"22","author":"Waddell L","year":"2008","unstructured":"Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008, 22:238-43. 10.1177\/0269881107087976","journal-title":"J Psychopharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2880","article-title":"Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration","volume":"339","author":"Stone M","year":"2009","unstructured":"Stone M, Laughren T, Jones ML, et al.. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009, 339:b2880. 10.1136\/bmj.b2880","journal-title":"BMJ"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078015","article-title":"Expanding the black box - depression, antidepressants, and the risk of suicide","volume":"356","author":"Friedman RA","year":"2007","unstructured":"Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med. 2007, 356:2343-6. 10.1056\/NEJMp078015","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon M","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017, 78:e264-78. 10.4088\/JCP.16r10832","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert M","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011, 8:114-26. 10.1038\/nrendo.2011.156","journal-title":"Nat Rev Endocrinol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27:596-601. 10.2337\/diacare.27.2.596","journal-title":"Diabetes Care"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S133205","article-title":"Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solmi M","year":"2018","unstructured":"Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018, 12:1215-38. 10.2147\/DDDT.S133205","journal-title":"Drug Des Devel Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai R","year":"2010","unstructured":"Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010, 67:26-36. 10.1001\/archgenpsychiatry.2009.175","journal-title":"Arch Gen Psychiatry"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1229.104497","article-title":"Polypharmacy in psychiatry: a review","volume":"11","author":"Kukreja S","year":"2013","unstructured":"Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013, 11:82-99. 10.4103\/0973-1229.104497","journal-title":"Mens Sana Monogr"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon N","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017, 17:230. 10.1186\/s12877-017-0621-2","journal-title":"BMC Geriatr"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.3.469","article-title":"Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?","volume":"159","author":"Zimmerman M","year":"2002","unstructured":"Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am J Psychiatry. 2002, 159:469-73. 10.1176\/appi.ajp.159.3.469","journal-title":"Am J Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin T","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015, 16:495. 10.1186\/s13063-015-1023-4","journal-title":"Trials"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033559","article-title":"Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs","volume":"7","author":"Konrat C","year":"2012","unstructured":"Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One. 2012, 7:e33559. 10.1371\/journal.pone.0033559","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2522","article-title":"Considerations for pregnant and lactating women in clinical drug development: a regulatory perspective","volume":"111","author":"Bhatnagar S","year":"2022","unstructured":"Bhatnagar S, Bello CL, Pang L, Mugundu G. Considerations for pregnant and lactating women in clinical drug development: a regulatory perspective. Clin Pharmacol Ther. 2022, 111:561-8. 10.1002\/cpt.2522","journal-title":"Clin Pharmacol Ther"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.5150","article-title":"Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010","volume":"317","author":"Downing NS","year":"2017","unstructured":"Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA. 2017, 317:1854-63. 10.1001\/jama.2017.5150","journal-title":"JAMA"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2311","article-title":"The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety","volume":"21","author":"Robb MA","year":"2012","unstructured":"Robb MA, Racoosin JA, Sherman RE, et al.. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf. 2012, 21:9-11. 10.1002\/pds.2311","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref55","unstructured":"Sentinel Operations Center, U.S. Food and Drug Administration. PDUFA VII commitment: an assessment of the Sentinel System (2022 to 2024). (2025). Accessed: October 6, 2026: https:\/\/www.fda.gov\/industry\/prescription-drug-user-fee-amendments\/pdufa-vii-commitment-assessment-sentinel-system-20...."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2015.02.004","article-title":"Utilizing social media data for pharmacovigilance: a review","volume":"54","author":"Sarker A","year":"2015","unstructured":"Sarker A, Ginn R, Nikfarjam A, et al.. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform. 2015, 54:202-12. 10.1016\/j.jbi.2015.02.004","journal-title":"J Biomed Inform"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocu041","article-title":"Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features","volume":"22","author":"Nikfarjam A","year":"2015","unstructured":"Nikfarjam A, Sarker A, O'Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015, 22:671-81. 10.1093\/jamia\/ocu041","journal-title":"J Am Med Inform Assoc"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.18653\/v1\/W19-3203","article-title":"Overview of the Fourth Social Media Mining for Health (SMM4H) shared tasks at ACL 2019","author":"Weissenbacher D","year":"2019","unstructured":"Weissenbacher D, Sarker A, Magge A, et al.. Overview of the Fourth Social Media Mining for Health (SMM4H) shared tasks at ACL 2019. Proceedings of the Fourth Social Media Mining for Health Applications Workshop & Shared Task. Association for Computational Linguistics, Florence, Italy; 2019. 21-30. 10.18653\/v1\/W19-3203"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-00323-1","article-title":"The future of digital health with federated learning","volume":"3","author":"Rieke N","year":"2020","unstructured":"Rieke N, Hancox J, Li W, et al.. The future of digital health with federated learning. NPJ Digit Med. 2020, 3:119. 10.1038\/s41746-020-00323-1","journal-title":"NPJ Digit Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187121","article-title":"ADEPt, a semantically-enriched pipeline for extracting adverse drug events from free-text electronic health records","volume":"12","author":"Iqbal E","year":"2017","unstructured":"Iqbal E, Mallah R, Rhodes D, et al.. ADEPt, a semantically-enriched pipeline for extracting adverse drug events from free-text electronic health records. PLoS One. 2017, 12:e0187121. 10.1371\/journal.pone.0187121","journal-title":"PLoS One"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300919","article-title":"using large language models to extract adverse events from surveillance reports - a use case with influenza vaccine adverse events","volume":"19","author":"Li Y","year":"2024","unstructured":"Li Y, Li J, He J, Tao C. using large language models to extract adverse events from surveillance reports - a use case with influenza vaccine adverse events. PLoS One. 2024, 19:e0300919. 10.1371\/journal.pone.0300919","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.18653\/v1\/2024.eacl-short.30","article-title":"Leveraging ChatGPT in pharmacovigilance event extraction: an empirical study","author":"Sun Z","year":"2024","unstructured":"Sun Z, Pergola G, Wallace BC, He Y. Leveraging ChatGPT in pharmacovigilance event extraction: an empirical study. Proceedings of the 18th Conference of the European Chapter of the Association for Computational Linguistics. Association for Computational Linguistics, St. Julian\u2019s, Malta; 2024. 344-57. 10.18653\/v1\/2024.eacl-short.30"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14155490","article-title":"Large language models for adverse drug events: a clinical perspective","volume":"14","author":"Zitu MM","year":"2025","unstructured":"Zitu MM, Owen D, Manne A, Wei P, Li L. Large language models for adverse drug events: a clinical perspective. J Clin Med. 2025, 14:5490. 10.3390\/jcm14155490","journal-title":"J Clin Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.2196\/57824","article-title":"Applying AI to structured real-world data for pharmacovigilance purposes: scoping review","volume":"26","author":"Dimitsaki S","year":"2024","unstructured":"Dimitsaki S, Natsiavas P, Jaulent MC. Applying AI to structured real-world data for pharmacovigilance purposes: scoping review. J Med Internet Res. 2024, 26:e57824. 10.2196\/57824","journal-title":"J Med Internet Res"},{"key":"ref65","article-title":"RETAIN: an interpretable predictive model for healthcare using reverse time attention mechanism","author":"Choi E","year":"2016","unstructured":"Choi E, Bahadori MT, Sun J, Kulas J, Schuetz A, Stewart W. RETAIN: an interpretable predictive model for healthcare using reverse time attention mechanism. Advances in Neural Information Processing Systems. Curran Associates, Inc., Red Hook, NY; 2016. 3504-12."},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1038\/srep26094","article-title":"Deep patient: an unsupervised representation to predict the future of patients from the electronic health records","volume":"6","author":"Miotto R","year":"2016","unstructured":"Miotto R, Li L, Kidd BA, Dudley JT. Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. Sci Rep. 2016, 6:26094. 10.1038\/srep26094","journal-title":"Sci Rep"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2196\/mental.5165","article-title":"New tools for new research in psychiatry: a scalable and customizable platform to empower data driven smartphone research","volume":"3","author":"Torous J","year":"2016","unstructured":"Torous J, Kiang MV, Lorme J, Onnela JP. New tools for new research in psychiatry: a scalable and customizable platform to empower data driven smartphone research. JMIR Ment Health. 2016, 3:e16. 10.2196\/mental.5165","journal-title":"JMIR Ment Health"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11295","article-title":"Digital phenotyping: technology for a new science of behavior","volume":"318","author":"Insel TR","year":"2017","unstructured":"Insel TR. Digital phenotyping: technology for a new science of behavior. JAMA. 2017, 318:1215-6. 10.1001\/jama.2017.11295","journal-title":"JAMA"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol EJ","year":"2019","unstructured":"Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019, 25:44-56. 10.1038\/s41591-018-0300-7","journal-title":"Nat Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"Rajkomar A","year":"2019","unstructured":"Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019, 380:1347-58. 10.1056\/NEJMra1814259","journal-title":"N Engl J Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax2342","article-title":"Dissecting racial bias in an algorithm used to manage the health of populations","volume":"366","author":"Obermeyer Z","year":"2019","unstructured":"Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019, 366:447-53. 10.1126\/science.aax2342","journal-title":"Science"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biodatasci-092820-114757","article-title":"Ethical machine learning in healthcare","volume":"4","author":"Chen IY","year":"2021","unstructured":"Chen IY, Pierson E, Rose S, Joshi S, Ferryman K, Ghassemi M. Ethical machine learning in healthcare. Annu Rev Biomed Data Sci. 2021, 4:123-44. 10.1146\/annurev-biodatasci-092820-114757","journal-title":"Annu Rev Biomed Data Sci"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01157-4","article-title":"\"Artificial intelligence\" for pharmacovigilance: ready for prime time?","volume":"45","author":"Ball R","year":"2022","unstructured":"Ball R, Dal Pan G. \"Artificial intelligence\" for pharmacovigilance: ready for prime time?. Drug Saf. 2022, 45:429-38. 10.1007\/s40264-022-01157-4","journal-title":"Drug Saf"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-01001-7","article-title":"Artificial intelligence, real-world automation and the safety of medicines","volume":"44","author":"Bate A","year":"2021","unstructured":"Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf. 2021, 44:125-32. 10.1007\/s40264-020-01001-7","journal-title":"Drug Saf"},{"key":"ref75","unstructured":"Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products. (2025). Accessed. October 6, 2026: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-s...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/531773-artificial-intelligence-enabled-pharmacovigilance-for-neuropsychiatric-therapies-advancing-us-drug-safety-surveillance-and-regulatory-decision-making","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:22:10Z","timestamp":1791901330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/531773-artificial-intelligence-enabled-pharmacovigilance-for-neuropsychiatric-therapies-advancing-us-drug-safety-surveillance-and-regulatory-decision-making"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":75,"URL":"https:\/\/doi.org\/10.7759\/cureus.117858","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}